Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceutical Chemicals
Gilead CEO Milligan to step down
by Lisa M. Jarvis
July 28, 2018
| A version of this story appeared in
Volume 96, Issue 31
John F. Milligan will step down as head of Gilead Sciences at the end of the year. Milligan has spent his entire career at the Foster City, Calif.-based biotech firm, ascending to president in 2008 and CEO in 2016. He took over the top role at a time when Gilead was under pressure to make a splashy acquisition that could help offset an expected sales dive for its hepatitis C drug franchise; the company subsequently paid nearly $12 billion for CAR-T therapy-focused Kite Pharma. Milligan’s successor has yet to be named.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X